However, in HPFS, higher levels of osteocalcin (HRs [95% CIs] with Q1 as reference: 1.67 [0.80-3.49], 0.59 [0.25-1.41], 1.05 [0.46-2.43], and 0.37 [0.13-1.04] for quintiles 2 through 5, respectively; P for trend .02) and sclerostin (HRs [95% CIs] with Q1 as reference: 0.92 [0.45-1.86], 0.94 [0.46-1.91], 0.42 [0.18-0.96], and 0.22 [0.09-0.54] for quintiles 2 through 5, respectively, in combined models; P for trend <.001) associated with reduced risk of hip fracture (Table 2; Figs. 1 and 2). The gene discussed is SOST; the disease is hip fracture.